NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity

scientific article

NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1161/CIRCULATIONAHA.105.576850
P698PubMed publication ID16330681
P5875ResearchGate publication ID7438303

P50authorHeike BickeböllerQ58049828
Gerd HasenfussQ61457522
Anke KruegerQ112457045
Michael PfreundschuhQ1928879
Peter NürnbergQ2077335
P2093author name stringMarkus Loeffler
Heike Bickeböller
Jürgen Brockmöller
Albert Rosenberger
Lorenz Trümper
Leszek Wojnowski
Markus Schirmer
Eun-Kyung Suk
Mohammad Reza Toliat
Heidi Hahn
Mladen Tzvetkov
Albrecht Schmidt
Bettina Kulle
Stefan Vonhof
Marita Kloess
Gregor Schlüter
Silvia Seifert
P2860cites workAldose reductase induction: a novel response to oxidative stress of smooth muscle cellsQ28579062
P433issue24
P407language of work or nameEnglishQ1860
P921main subjectmultiple drug resistanceQ643839
P304page(s)3754-3762
P577publication date2005-12-05
P1433published inCirculationQ578091
P1476titleNAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity
P478volume112

Reverse relations

cites work (P2860)
Q36004460A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer
Q37293202A discovery study of daunorubicin induced cardiotoxicity in a sample of acute myeloid leukemia patients prioritizes P450 oxidoreductase polymorphisms as a potential risk factor.
Q54360840ABCC1 polymorphism Arg723Gln (2168G> A) is associated with lung cancer susceptibility in a Chinese population.
Q41709561ABCG2 and NCF4 polymorphisms are associated with clinical outcomes in diffuse large B-cell lymphoma patients treated with R-CHOP.
Q38357704Advanced heart failure due to cancer therapy
Q57302751Adverse drug reactions and pharmacogenomics: recent advances
Q46008254Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21.
Q53128895Analyzing the clinical actionability of germline pharmacogenomic findings in oncology.
Q34639876Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment
Q38542462Anthracycline-Induced Cardiomyopathy in Adults
Q37342407Anthracycline-induced cardiotoxicity: prospective cohort study from Pakistan
Q38025714Antineoplastic drug-induced bradyarrhythmias.
Q92108669Antitumour anthracyclines: progress and perspectives
Q89228158Association of CYP2C19*2 and ALDH1A1*1/*2 variants with disease outcome in breast cancer patients: results of a global screening array
Q94938440Association of GSTM1 null variant with anthracycline-related cardiomyopathy after childhood cancer-A Children's Oncology Group ALTE03N1 report
Q53564509Association of NADPH oxidase polymorphisms with anthracycline-induced cardiotoxicity in the RICOVER-60 trial of patients with aggressive CD20(+) B-cell lymphoma.
Q36804526Association of anthracycline-related cardiac histological lesions with NADPH oxidase functional polymorphisms
Q28478256Autophagy inhibition enhances daunorubicin-induced apoptosis in K562 cells
Q38015746Biological drugs: classic adverse effects and new clinical evidences
Q55208199CATCH-KB: Establishing a Pharmacogenomics Variant Repository for Chemotherapy-Induced Cardiotoxicity.
Q37350809CELF4 Variant and Anthracycline-Related Cardiomyopathy: A Children's Oncology Group Genome-Wide Association Study
Q38313870Cancer chemotherapy and cardiac arrhythmias: a review.
Q38093137Cancer pharmacogenomics in children: research initiatives and progress to date.
Q36887091Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues.
Q33671281Candidate Gene Association Studies of Anthracycline-induced Cardiotoxicity: A Systematic Review and Meta-analysis.
Q38735433Cardiac Complications of Cancer Therapy: Pathophysiology, Identification, Prevention, Treatment, and Future Directions
Q36957758Cardiac side effects of anticancer treatments: new mechanistic insights
Q28068290Cardio-Oncology: A Focused Review of Anthracycline-, Human Epidermal Growth Factor Receptor 2 Inhibitor-, and Radiation-Induced Cardiotoxicity and Management
Q39078275Cardio-Oncology: Progress in Diagnosis and Treatment of Cardiac Dysfunction.
Q49909927Cardio-oncology: conflicting priorities of anticancer treatment and cardiovascular outcome
Q57108766Cardio-oncology: protecting the heart from curative breast cancer treatment
Q39270177Cardiotoxicity and cardiomyopathy in children and young adult survivors of hematopoietic stem cell transplant.
Q33619867Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials
Q41704131Cardiotoxicity of cancer chemotherapy: identification, prevention and treatment
Q88504622Cardiovascular Risk in Cancer Survivors
Q89565308Cardiovascular diseases in survivors of childhood cancer
Q37430831Cardiovascular toxicity caused by cancer treatment: strategies for early detection
Q90415345Chemotherapy Related Severe Cardiac Dysfunction - Case Report
Q39415815Chemotherapy-induced cardiotoxicity in children
Q35222202Chemotherapy-induced weakness and fatigue in skeletal muscle: the role of oxidative stress
Q38231301Chemotherapy-related cardiomyopathy: a neglected aspect of cancer survivorship
Q37390119Chronic health conditions in childhood cancer survivors: is it all treatment-related--or do genetics play a role?
Q37159230Clinical and Genetic Determinants of Cardiomyopathy Risk among Hematopoietic Cell Transplantation Survivors
Q49136273Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients
Q64900509Clinical ascertainment of health outcomes in Asian survivors of childhood cancer: a systematic review.
Q52928931Contraindication labelling changes in the United States and Germany.
Q38845535Current views on anthracycline cardiotoxicity.
Q37997817Disparities in subgroup populations enrolled in lung cancer trials
Q37834445Do pharmacokinetic polymorphisms explain treatment failure in high-risk patients with neuroblastoma?
Q35048393Doxorubicin pathways: pharmacodynamics and adverse effects
Q35775234Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model
Q92677814Doxorubicin-Induced Cardiomyopathy in Children
Q37998724Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies
Q91620854Drug-drug-gene interactions and adverse drug reactions
Q46987056Dystrophin-deficiency increases the susceptibility to doxorubicin-induced cardiotoxicity
Q51093490Effects of ranolazine in a model of doxorubicin-induced left ventricle diastolic dysfunction.
Q36186203Elevated glutathione is not sufficient to protect against doxorubicin-induced nuclear damage in heart in multidrug resistance-associated protein 1 (Mrp1/Abcc1) null mice
Q90614437Ethnogeographic and inter-individual variability of human ABC transporters
Q88536476Evaluation of a polymorphism in MYBPC3 in patients with anthracycline induced cardiotoxicity
Q41430035Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines
Q40039502Exome array analysis identifies ETFB as a novel susceptibility gene for anthracycline-induced cardiotoxicity in cancer patients
Q28475976Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition
Q39337368Functional characterization of ABCC2 promoter polymorphisms and allele-specific expression.
Q39403980Functional characterization of protein variants of the human multidrug transporter ABCC2 by a novel targeted expression system in fibrosarcoma cells
Q93106057Genetic Variants Associated With Cancer Therapy-Induced Cardiomyopathy
Q37167800Genetic determinants of drug response in heart failure
Q34062500Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma
Q37830057Genetic polymorphisms in placental transporters: implications for fetal drug exposure to oral antidiabetic agents
Q46611556Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer
Q48744224Genetic polymorphisms of NAD(P)H oxidase: variation in subunit expression and enzyme activity
Q37481450Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs
Q37227651Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation
Q37271466Genetic variants contributing to daunorubicin-induced cytotoxicity
Q58862883Genetic variants inSLC22A17 and SLC22A7are associated with anthracycline-induced cardiotoxicity in children
Q46169842Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure
Q38765132Genome-wide association and pathway analysis of left ventricular function after anthracycline exposure in adults.
Q51816225Genome-wide association study of cardiotoxicity in the NCCTG N9831 (Alliance) adjuvant trastuzumab trial.
Q48171906Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer
Q36800903Genomic profiling reveals the potential role of TCL1A and MDR1 deficiency in chemotherapy-induced cardiotoxicity
Q37473789Genomics, transcriptional profiling, and heart failure
Q42727098Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study
Q37614177Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer
Q38868285High-sensitive cardiac troponin-I facilitates timely detection of subclinical anthracycline-mediated cardiac injury
Q36384257Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent
Q38874111Human Induced Pluripotent Stem Cells as a Platform for Personalized and Precision Cardiovascular Medicine.
Q35086334Hyaluronan synthase 3 variant and anthracycline-related cardiomyopathy: a report from the children's oncology group.
Q51782486Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.
Q33441706Impact of NADPH oxidase functional polymorphisms in acute myeloid leukemia induction chemotherapy
Q38199535Importance of ABCC1 for cancer therapy and prognosis.
Q40670821In vitro and in vivo antineoplastic and immunological effects of pterocarpanquinone LQB-118.
Q36406442Individual responses to chemotherapy-induced oxidative stress
Q46801702Induced Pluripotent Stem Cell-Derived Cardiomyocytes: A Platform for Testing For Drug Cardiotoxicity
Q43253475Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood
Q52717628Inhibition of TRPA1 Attenuates Doxorubicin-Induced Acute Cardiotoxicity by Suppressing Oxidative Stress, the Inflammatory Response, and Endoplasmic Reticulum Stress.
Q35913104Interindividual variability in hepatic expression of the multidrug resistance-associated protein 2 (MRP2/ABCC2): quantification by liquid chromatography/tandem mass spectrometry
Q43291060Late effects surveillance system after childhood cancer in Germany, austria and parts of Switzerland--update 2009.
Q34095952Limitations in Adjuvant Breast Cancer Therapy: The Predictive Potential of Pharmacogenetics and Pharmacogenomics.
Q33705877Long-term consequences of hematopoietic stem cell transplantation: current state of the science
Q37023604Loss of Mrp1 Potentiates Doxorubicin-Induced Cytotoxicity in Neonatal Mouse Cardiomyocytes and Cardiac Fibroblasts
Q36186168Loss of multidrug resistance-associated protein 1 potentiates chronic doxorubicin-induced cardiac dysfunction in mice
Q36054324Lovastatin protects human endothelial cells from the genotoxic and cytotoxic effects of the anticancer drugs doxorubicin and etoposide
Q37563014Maximizing the Benefit-Cost Ratio of Anthracyclines in Metastatic Breast Cancer: Case Report of a Patient with a Complete Response to High-Dose Doxorubicin.
Q30439608Mechanisms of Anthracycline Cardiotoxicity and Strategies to Decrease Cardiac Damage
Q42559258Mitochondria death/survival signaling pathways in cardiotoxicity induced by anthracyclines and anticancer-targeted therapies
Q34467407Multidrug resistance protein 1 (MRP1, ABCC1), a "multitasking" ATP-binding cassette (ABC) transporter
Q28468693Multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphism: from discovery to clinical application
Q35123683Multivariable regression analysis of febrile neutropenia occurrence in early breast cancer patients receiving chemotherapy assessing patient-related, chemotherapy-related and genetic risk factors
Q27001094NADPH oxidases in heart failure: poachers or gamekeepers?
Q37176104NOX enzymes as novel targets for drug development
Q35549037National Cancer Institute-National Heart, Lung and Blood Institute/pediatric Blood and Marrow Transplant Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: long-term organ damage a
Q30427656Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs
Q38112350Novel aspects of ROS signalling in heart failure
Q64269386Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity
Q34322162Nox2 NADPH oxidase promotes pathologic cardiac remodeling associated with Doxorubicin chemotherapy
Q45770434Occupational risk assessment of genotoxicity and oxidative stress in workers handling anti-neoplastic drugs during a working week
Q46253112Oxidative Stress and Cellular Response to Doxorubicin: A Common Factor in the Complex Milieu of Anthracycline Cardiotoxicity.
Q36568908Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.
Q38876257Pathways of cardiac toxicity: comparison between chemotherapeutic drugs doxorubicin and mitoxantrone.
Q42130469Patient-Specific Pluripotent Stem Cells in Doxorubicin Cardiotoxicity: A New Window Into Personalized Medicine
Q37532571Pharmacogenetics in heart failure: promises and challenges
Q57302675Pharmacogenetics of Adverse Drug Reactions
Q64355486Pharmacogenetics of Chemotherapy-Induced Cardiotoxicity
Q38856218Pharmacogenetics of anthracyclines.
Q37932556Pharmacogenetics of genes across the doxorubicin pathway.
Q38933314Pharmacogenetics of irinotecan, doxorubicin and docetaxel transporters in Asian and Caucasian cancer patients: a comparative review.
Q64077129Pharmacogenomic and Pharmacotranscriptomic Profiling of Childhood Acute Lymphoblastic Leukemia: Paving the Way to Personalized Treatment
Q38887034Pharmacogenomics and the treatment of acute myeloid leukemia.
Q36637796Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity
Q38688039Pharmacogenomics in pediatric acute lymphoblastic leukemia: promises and limitations
Q27692687Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine
Q36441493Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy
Q37305039Pharmacogenomics: a tool for improving cancer chemotherapy
Q38003177Pharmacokinetic and pharmacogenetic determinants and considerations in chemotherapy selection and dosing in infants
Q35034995Plasma high sensitivity troponin T levels in adult survivors of childhood leukaemias: determinants and associations with cardiac function
Q33395469Polymorphism in multidrug resistance-associated protein gene 3 is associated with outcomes in childhood acute lymphoblastic leukemia
Q47137275Polymorphisms at microRNA binding sites of Ara-C and anthracyclines-metabolic pathway genes are associated with outcome of acute myeloid leukemia patients
Q53672562Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia.
Q55518023Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma.
Q37230408Predicting and preventing the cardiotoxicity of cancer therapy
Q38662111Preventing pediatric cardiomyopathy: a 2015 outlook
Q49037203Prevention and Treatment of Cardiac Dysfunction in Breast Cancer Survivors
Q38838517Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity
Q34774854Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug Resistance
Q36921775Risk factors for anthracycline-associated cardiotoxicity
Q60924005Role of Endothelium in Doxorubicin-Induced Cardiomyopathy
Q35327266Role of genetic susceptibility in development of treatment-related adverse outcomes in cancer survivors
Q39454435Selenium attenuates adriamycin-induced cardiac dysfunction via restoring expression of ATP-sensitive potassium channels in rats
Q42678476Signalling mechanisms underlying doxorubicin and Nox2 NADPH oxidase-induced cardiomyopathy: involvement of mitofusin-2.
Q37473480Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the D
Q48143732State of the art review: Chemotherapy-induced cardiotoxicity in children.
Q38606067Systems biology approaches to adverse drug effects: the example of cardio-oncology
Q41313867TRPC3 Channels in Cardiac Fibrosis.
Q35840905The G671V variant of MRP1/ABCC1 links doxorubicin-induced acute cardiac toxicity to disposition of the glutathione conjugate of 4-hydroxy-2-trans-nonenal
Q38200683The emerging era of pharmacogenomics: current successes, future potential, and challenges
Q79536301The interleukin-10 gene promoter polymorphism -1087AG does not correlate with clinical outcome in non-Hodgkin's lymphoma
Q38190105The more patients you treat, the more you cure: managing cardiotoxicity in the treatment of aggressive non-Hodgkin lymphoma
Q52982588The role and clinical effectiveness of multimodality imaging in the management of cardiac complications of cancer and cancer therapy.
Q37734911Transgenic expression of the human MRP2 transporter reduces cisplatin accumulation and nephrotoxicity in Mrp2-null mice.
Q37721782Unexpected doxorubicin-mediated cardiotoxicity in sisters: possible role of polymorphisms in histamine n-methyl transferase
Q34065294Urinary coproporphyrin I/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance
Q34897941Urinary elimination of coproporphyrins is dependent on ABCC2 polymorphisms and represents a potential biomarker of MRP2 activity in humans
Q46409053Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children.

Search more.